Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Molecular Characterization of Premalignant Lesions in Pancreatic Cancer

EF 2020-21

Résumé
Pancreatic cancer is a lethal disease with only 9% of patients surviving past 5 years. Patients are often diagnosed late and have rapidly deteriorating conditions. Early detection has the potential to increase survival by 30-40%, though efforts are hindered by the lack of understanding of how certain premalignant lesions can initiate and progress to pancreatic cancer. The most common precursor lesions, referred to as PanINs, are currently thought to be initiated by the mutation of the gene KRAS alone; however, recent evidence suggests otherwise. Thus, to study the evolutionary progression of pancreatic cancer, I aim to determine the dysregulated pathways responsible for PanIN lesions by profiling their transcriptomic signatures. I hypothesize that KRAS mutations occur in conjunction with secondary pathway alterations to form PanINs. First, I will model the effects of KRAS activation in patient-derived, normal pancreatic cells in vitro. Then, I will verify the results and identify other altered pathways in PanINs from patient-derived tissue sections. To do this, I will use spatial transcriptomics, a novel technology that allows sequences to be mapped back onto a location in the original sample. This will allow for the identification of signatures specific to PanIN lesions, without losing precision from a decrease in resolution, or losing accuracy if confused with signatures of contaminating invasive tumors. Overall, this work will aid to inform the diagnosis and treatment of pancreatic cancer precursor lesions.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449685
Name
Gong Ling Xi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Molecular Characterization of Premalignant Lesions in Pancreatic Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancerization Of Duct; Carcinogenesis; Crispr; Gene Expression Profiling; Kras Oncogene; Molecular Evolution; Organoids; Pancreatic Cancer; Pancreatic Neoplasms; Spatial Transcriptomics
Abstract
Pancreatic cancer is a lethal disease with only 9% of patients surviving past 5 years. Patients are often diagnosed late and have rapidly deteriorating conditions. Early detection has the potential to increase survival by 30-40%, though efforts are hindered by the lack of understanding of how certain premalignant lesions can initiate and progress to pancreatic cancer. The most common precursor lesions, referred to as PanINs, are currently thought to be initiated by the mutation of the gene KRAS alone; however, recent evidence suggests otherwise. Thus, to study the evolutionary progression of pancreatic cancer, I aim to determine the dysregulated pathways responsible for PanIN lesions by profiling their transcriptomic signatures. I hypothesize that KRAS mutations occur in conjunction with secondary pathway alterations to form PanINs. First, I will model the effects of KRAS activation in patient-derived, normal pancreatic cells in vitro. Then, I will verify the results and identify other altered pathways in PanINs from patient-derived tissue sections. To do this, I will use spatial transcriptomics, a novel technology that allows sequences to be mapped back onto a location in the original sample. This will allow for the identification of signatures specific to PanIN lesions, without losing precision from a decrease in resolution, or losing accuracy if confused with signatures of contaminating invasive tumors. Overall, this work will aid to inform the diagnosis and treatment of pancreatic cancer precursor lesions.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gong, Ling Xi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~